OMER — Omeros Corporation

Omeros Corporation Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Income: $86.5 million ($1.22 per share), a significant turnaround from a net loss of $30.9 million ($0.47 per share) in Q3 2025.
• Non-GAAP Adjusted Net Income: $222.5 million ($3.14 per share), excluding a $136 million noncash charge related to embedded derivatives.
• Cash and Investments: $171.8 million as of December 31, 2025, up $135.7 million from Q3 2025.
• Debt Reduction: Used part of the $240 million upfront payment from Novo Nordisk to fully repay a $67.1 million term loan and a $17.1 million convertible note, leaving only $70.8 million in 2029 convertible notes outstanding.

2. Strategic Updates and Business Highlights

• Asset Sale to Novo Nordisk: Closed a $240 million upfront cash deal for zaltenibart, with potential total value up to $2.1 billion including milestones and royalties.
• FDA Approval of YARTEMLEA: Received approval for YARTEMLEA (narsoplimab) for treating TA-TMA, marking it as the first approved treatment for this condition.
• Commercial Launch: Preparations for YARTEMLEA's launch were initiated prior to approval, with a fully deployed sales force and early sales occurring shortly after launch.
• Market Strategy: Focus on educating transplant centers and securing formulary approvals; 50% of top 10 U.S. transplant centers have approved YARTEMLEA.

3. Forward Guidance and Outlook

• Financial Sustainability: YARTEMLEA expected to be financially self-sustaining in 2026, with a target for positive cash flow by 2027.
• Sales and Marketing Expenses: Anticipated increase in Q1 2026 due to ongoing commercial launch activities, while R&D expenses are expected to decrease as zaltenibart-related costs will be reimbursed.
• Patient Access and Adoption: Continued efforts to ensure timely reimbursement and expand physician education on TA-TMA and YARTEMLEA.

4. Bad News, Challenges, or Points of Concern

• Noncash Charges: The significant $136 million noncash charge from the mark-to-market adjustment on embedded derivatives could create volatility in reported results.
• Market Access Uncertainty: While early responses to YARTEMLEA have been positive, the company has not provided specific patient start numbers, indicating uncertainty in early adoption metrics.
• Regulatory Risks: Ongoing discussions with the FDA regarding additional preclinical information for the OMS527 program could delay further developments.

5. Notable Q&A Insights

• Formulary Approvals: The company is optimistic about achieving additional P&T committee approvals, with current approvals exceeding expectations.
• Real-World Usage of YARTEMLEA: Early usage patterns indicate a split between once-weekly and twice-weekly dosing, with a focus on educating transplant teams about the latter.
• Sales Force Feedback: Positive feedback from the sales team regarding receptivity from medical centers, though ongoing education is necessary to address any lingering questions or roadblocks.
• Milestone Confidence: Management expressed high confidence in receiving a $100 million milestone from Novo Nordisk, although specific triggers remain undisclosed.

Overall, Omeros Corporation demonstrated a strong financial performance in Q4 2025, marked by significant strategic advancements, particularly with YARTEMLEA, while navigating challenges related to market access and noncash financial metrics.